蛋白转化酶亚提利辛/凯类型9 (PCSK9) 和透析患者的临床结果
Claudia Torino1, Federico Carbone2,3, Patrizia Pizzini1
1Clinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Pisa, Italy.
European journal of clinical investigation
|May 11, 2024
概括
蛋白转化酶亚提利辛/素9型 (PCSK9) 水平与透析患者的整体死亡率无关. 然而,女性PCSK9升高显著增加心血管事件的风险,突出性别特异性关联.
科学领域:
- 科和心血管研究.
- 在慢性疾病中的生物标志物分析.
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 影响LDL受体水平和心血管风险.
- 以前的研究表明PCSK9和心血管事件之间存在性别依赖的联系,但这在透析人群中没有得到测试.
研究的目的:
- 研究透析患者PCSK9水平与全因和心血管死亡率之间的关联.
- 检查PCSK9对这一队列中死亡风险的潜在基于性别的效果修改.
主要方法:
- 对从PROGREDIRE队列中接受透析的1188名患者的分析.
- 通过酶相关免疫吸收剂测定测量PCSK9水平.
- 考克斯回归和效果修改分析被用于评估死亡结果.
主要成果:
- 未经调整的分析显示PCSK9与所有原因和心血管死亡率的增加相关.
- 这些关联在多变量调整后失去了统计学意义.
- 然而,相互作用分析显示,女性心血管事件的风险显著增加一倍 (HR1.88),但男性 (HR1.07),没有显著的p值效果修改 (p=0.02).
结论:
- 在透析患者中,PCSK9水平与全因死亡率无关.
- 升高的PCSK9独立地增加了心血管事件的风险,特别是在这个人群中的女性中,独立于其他风险因素.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:27Dialysis
301
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
301
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:25Antihypertensive Drugs: Direct Renin Inhibitors
601
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
601
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K